0367620 - FGÚ 2012 RIV US eng J - Journal Article
Kůs, Vladimír - Flachs, Pavel - Kuda, Ondřej - Bardová, Kristina - Janovská, Petra - Svobodová, Michaela - Macek Jílková, Zuzana - Rossmeisl, Martin - Wang-Sattler, R. - Yu, Z. - Illig, T. - Kopecký, Jan
Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet.
PLoS ONE. Roč. 6, č. 11 (2011), e27126. ISSN 1932-6203. E-ISSN 1932-6203
R&D Projects: GA MZd(CZ) NS10528
Grant - others:EC(XE) FP7-244995
Institutional research plan: CEZ:AV0Z50110509
Keywords : obesity * TZD * fish oil
Subject RIV: FB - Endocrinology, Diabetology, Metabolism, Nutrition
Impact factor: 4.092, year: 2011 ; AIS: 1.798, rok: 2011
DOI: https://doi.org/10.1371/journal.pone.0027126

We investigated whether pioglitazone (as well as rosiglitazone), a TZD-drug, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice were fed a high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with rosiglitazone; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with pioglitazone; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites, development obesity, glucose homeostasis, plasma lipid levels and gene expression were evaluated. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin. The beneficial effects of TZDs were further augmented by the combination treatments. Our results reveal differential effects of rosiglitazone and pioglitazone and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient’s therapy
Permanent Link: http://hdl.handle.net/11104/0202222